Biolab introduces CVD panel testing for genetic mutations Biolab, the exclusive Biomnis dealer in the Kingdom, recently introduced a CVD panel test for genetic mutations associated with blood clotting in the body, which is considered one of the latest tests in the diagnosis of heart disease.

CVD Panel testing identifies both genetic and acquired mutations that can lead to heart disease, such as myocardial infarction, strokes, congestive heart failure, heart rate disorders and valve issues.

Mutations covered in the test include mutation factor V Leiden, mutation factor R2, Prothrombin, B-fibrinogen, Plasminogen Activator Inhibitor, Platelet Glycoprotein, MTHFR C677T, MTHFR A1298C, Angoitensin Converting Enzyme, as well as clotting which include Apolipoprotein B and Apolipoprotein E.

The management of Biolab explained that the importance of this cutting-edge diagnostic approach stems from its high accuracy in diagnosing hereditary conditions in general, making it a vital tool of preventive medicine and an ideal complement to conventional biochemical diagnostics.

This falls in line with Biolab's key objective, which is elevating the standards of healthcare in the Kingdom and empowering the public with viable early diagnosis tools capable of identifying potential health risks long before they present symptoms.

Biolab is a pioneer in applying advances in medicine and science to laboratory testing, providing a broad range of medical diagnostic services to individuals, physicians, hospitals and other laboratories, in addition to offering a wide array of medical, scientific and consultancy services in the fields of health and diagnostics.

Leveraging on cutting-edge technology, high caliber staff and an extensive insurance and bank affiliate network, Biolab offers its patients an unparalleled premium experience, prioritizing reliability, accountability and convenience.